1 / 21

Current Global Pharma Developments-Challenges and Opportunities

Current Global Pharma Developments-Challenges and Opportunities. P.U.M.Rao Retd. Addl. Industrial Adviser(Pharma), Govt. Of India. The Race for Quality has no

anne-woodward
Download Presentation

Current Global Pharma Developments-Challenges and Opportunities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Current Global Pharma Developments-Challenges and Opportunities P.U.M.Rao Retd. Addl. Industrial Adviser(Pharma), Govt. Of India

  2. The Race for Quality has no finishing Line………

  3. Global Pharma Industry 2008-09 • Global drug sales projected at $ 773 Bn with low growth of 4.8% in 2008.Further slowdown expected in 2009 • North America sales- $ 312 Bn, • Europe sales $ 247 Bn, Japan $ 76 Bn, • Latin America $ 47 Bn growing +12%, • Asia/Africa/Australia together $ 91 Bn growing +15% • patent expiries, slowdown in new product launches, hurdles imposed by payers on market access, world financial crisis are some reasons for reduced growth

  4. Global Pharma(contd) • Oncology top therapeutic class $ 48 Bn sales growing at 11%. To reach $75 - 80 Bn by 2012. • Aggregate value of biotechnology drugs sales +$ 75 Billion in 2007 are estimated to grow to $169 billion in 2014. • Lipid Regulators($ 34 Bn),Respiratory($ 31 Bn), Antidiabetics($ 27 Bn), Antiulcers( $ 26 Bn), CVD($ 23 Bn) are the other top groups • U.S. Prescription drug Sales which grew 1.3 Percent in 2008 to $ 291 Billion is expected to decline by 1-2 percent in 2009

  5. Global Pharma Highlights • Top 50 pharmaceutical companies accounted for prescription drug sales of $ 558 billion in 2008. • New Drugs in development gone up to 9605( 2009) from 5930 (1998) • Currently there are 100 blockbuster drugs, 22 biotech productsare part of this. • 32 NCEs launched in 2008 compared to 25 in 2007.

  6. Top Product Sales 2008($ Bn)

  7. Global Pharma Developments ● Serious profit setbacks • Mergers & Acquisitions. • Prohibitive R&D costs • Changing Regulatory environment • Threat from generics • More outsourcing • Emergence of new players • ICH-quality risk managementQ8, Q9 and Q10 guidelines.

  8. Drug Patent Expiry

  9. Big Pharma M & A

  10. Indian Pharma Profile

  11. Current Indian pharma export profile • Exports of Drugs, Pharma and Finechem amounted to Rs 32051 Crores during 2008-09 (Apr -_Jan) • The Biopharma exports touched Rs 3999 Crores in 2007-08 • Exports to over 200 destinations including small islands like Kiribati • Europe, North America together account for half of exports • Share of dosage exports 52% - a noteworthy achievement • World’s No. 1 Pharma market USA also India’s top destination • Africa is biggest with 54 destinations • Global presence of India in the critical antiretroviral supply is now part of history.

  12. Major export destinations(value Rs Mil)

  13. Major API Exports(2007-08)

  14. Major Dosage Form exports(2007-08)

  15. Government Initiatives for Pharma sector • 100 % FDI permitted through Automatic route • Technology freely importable both Lumpsum, Royalty applicable • Foreign Trade policy instruments-Advance Authorisation, DEPB, EPCG • Export facilitation- MAI, MDI • New moves - Focus Markets, • R&D initiatives – funding • In house R&D recognition • Modernisation • Registration system streamlined for import of drugs - both site and product registration • product patents for drugs, food and agrochemicals since 2005

  16. Global Generic industry • Global generics Sale $78 billion as per IMSH. Growth down to 3.6 % from 11.4 % in 2007 • top eight global markets – the U.S., Germany, France, the U.K., Canada, Italy, Spain and Japan account for 84 percent of total generics sales . • Generics growth 10.2 % in Japan, 16.9 % in France, 12.5 % in Italy and 10.5 % in Spain. • Top 10 generics companies 47 percent share of the generics market worldwide. • Three leading generics manufacturers – Teva ( 11 % market share), Sandoz ( 9 %) and Mylan ( 8 %). • Generics companies to benefit as products generating $139 billion in branded sales in the top eight world markets lose their patent protection through 2012

  17. generic medicine policies of European governments

  18. Opportunities • Why New Markets - what’s happening in US, Europe • Outsourcing opportunities. Collaboration, Tie ups • BT Acquisitions • Prevalence of Different Strategies – • Growth Areas for products • Eco-innovation driving greener product development • Cooperate not compete model • FTAs- Setting up JVs to access new markets.

  19. Concept to Goal of ASEAN pharmaceutical harmonization • $ 13 Billion ASEAN pharma market presents growing opportunities • 10 ASEAN member countries formed PPWG in 1999 – A Partnership of Indonesia, Malaysia, Singapore, Thailand, Philippines, South Korea, Vietnam, Laos, Mynamar, Brunei • Studied harmonization of procedures and regulatory system towards achieving MRA • ASEAN CTD and other regulatory parameters like BA adopted • Implementation through Working Group based on consultations and consensus • Resources, Training taken care off • ASEAN GMP finally in place through a decade of dedicated exercise • Implementation January 2011

  20. Impediments • Non Tariff Barriers • Effect of Free trade agreements • Growing imports. • Absence of regulatory cooperation • Pricing pressures in US. • New approach by overseas API Mfrs - risk strategy • Take over Blues • Authorized Generics • REACH • Increased FDA scrutiny of overseas API facilities • Lack of Accreditation of Indian testing labs by vendors

  21. Thank you

More Related